8:25 am Chair’s Opening Remarks

Phenomapping the HFpEF Population to Understand Mechanistic Targets

8:30 am Identification of a HFpEF Subpopulation Sensitive to Stimulation of the Soluble Guanylate

Synopsis

  • Assess the heterogeneity and numerous comorbidities of the general HFpEF population
  • Understand how the pathophysiology of distinct patient sub-population may help to identify specific treatment options
  • Identify an important HFpEF subpopulation where a specific treatment option potentially addresses the specific pathophysiology of this population

9:00 am Targeting Peripheral & Cardiac Metabolism for Therapeutic Benefits in Heart Failure

Synopsis

  • Evaluate how the metabolic HFpEF pheno-group is associated with obesity and diabetes and is increasing in prevalence
  • Discover how metabolic therapies such as exercise have shown benefit in HFpEF across multiple trials
  • Learn how targeting dysregulated branched-chain amino acid metabolism has demonstrated efficacy in preclinical HFpEF models

9:30 am Preclinical Models of HFpEF: Translating back from Patient Phenotypes

  • Flora Sam Senior Medical Fellow, Early Phase Cardiovascular Research – Diabetes & Complications Advanced Heart Failure Cardiologist & Physician-scientist, Eli Lilly

Synopsis

  • Learn how although HFpEF clinical trials have been heterogenous, failures of these trials have pointed the figure back to preclinical models.
  • Discuss the lack of understanding in the preclinical literature that “diastolic heart failure” (HFpEF) is not synonymous with diastolic dysfunction
  • Analyze how while there is a role to understand the clinical phenotypes (i.e. multiple co-morbidities), it remains important to have a reductionist view too
  • What is the the contribution of hypertension or obese or T2DM alone?
  • What phenotypes are we missing in preclinical models?

10:00 am Moderated Discussion – What Are the Possible Therapeutic Options for Different Phenotypes?

  • Andreas Busch Chief Scientific Officer, Cyclerion Therapeutics
  • Rachel Roth Flach Senior Principal Scientist, Pfizer
  • Flora Sam Senior Medical Fellow, Early Phase Cardiovascular Research – Diabetes & Complications Advanced Heart Failure Cardiologist & Physician-scientist, Eli Lilly

10:30 am Morning Break & Networking

Synopsis

Have in-person 1-to-1 business introductions with other leaders and decision-makers prioritizing HFpEF drug development

Interrogating the Role of EMPEROR-Preserved & GLP1 in the Context of Heart Failure

11:15 am Translating the Role of GLP 1 in Heart Failure in the Cardiorenal syndrome

  • Jyothis George Vice President - Clinical Development, Medical Affairs & Regulatory, , Novo Nordisk

Synopsis

  • Discuss how GLP 1 improves diastolic function and survival in HFpEF patients
  • Understand how it has emerged as a promising drug to restore metabolic perturbations, and may have value in the treatment of the cardiometabolic HFpEF phenotype

11:45 am Targeting EMPEROR PRESERVE as an Entry Point in HFpEF Drug Development Success

  • Uli Broedl Head of Global Clinical Development & Operations, Boehringer Ingelheim

Synopsis

  • Examine the results and findings of EMPEROR-Preserved
  • Evaluate the learnings obtained from the trial
  • Understand the impact of EMPEROR-Preserved on future developments in HFpEF

12:15 pm Moderated Discussion – Should We Be Planning for Combination Approaches?

  • Jyothis George Vice President - Clinical Development, Medical Affairs & Regulatory, , Novo Nordisk
  • Uli Broedl Head of Global Clinical Development & Operations, Boehringer Ingelheim

12:45 pm Networking Lunch

Evaluating the Efficacy of Drugs & Therapies in the Quality of Life for HFpEF Patients

1:45 pm Symptoms, Physical Limitation & Quality of Life – Burden & Relevance in HFpEF

  • Ola Vedin Global Medical Director Heart Failure, Boehringer Ingelheim

Synopsis

  • Define and measure symptom burden, physical limitation and QoL in HFpEF
  • To what extent is symptom burden and physical limitation in HFpEF driven by HF vs other comorbidities?
  • Explore the impact of current treatment alternatives on symptoms and QoL in HFpEF

2:15 pm Similarities & Differences between HFrEF & HFpEF: Insight into Novel Therapies

  • Gavin Oudit Cardiologist & Clinician-Scientist, Mazankowski Alberta Heart Institute

Synopsis

  • Study the cellular and molecular differences between HFpEF and HFrEF
  • Realize the role of inflammation and endothelial damage in HFpEF
  • Targeting the apelin pathway as a novel therapy

2:45 pm Interrogating the role for cardiomyocytes in HFpEF – is there improvement?

Synopsis

  • Study the cellular and molecular differences between HFpEF and HFrEF
  • Realize the role of inflammation and endothelial damage in HFpEF
  • Targeting the apelin pathway as a novel therapy

3:15 pm Moderated Discussion – Outlining Methods to Improve the Quality of Life for HFpEF Patients

  • Gavin Oudit Cardiologist & Clinician-Scientist, Mazankowski Alberta Heart Institute
  • Ola Vedin Global Medical Director Heart Failure, Boehringer Ingelheim

Synopsis

  • What has been observed in previous trials with respect to mortality rates and what have interim analyses shown?
  • What steps have been taken to improve this definition for HFpEF patient?
  • How does changing the definition for quality of life subsequently alter the drug development industry?

3:45 pm Afternoon Break & Networking

Understanding HFpEF & Its Relationship with Other Comorbidities

4:30 pm Understanding the Cardio-Renal Relationship to Better Inform Drug Development Decisions

Synopsis

  • Gain expert insight into molecular pathways linking the cardiovascular and renal systems
  • Identify and validate mechanisms operating in both CVD and CKD as druggable targets
  • Should we routinely test CKD candidates for efficacy in CVD?

5:00 pm Is Heart Failure with Preserved Ejection Fraction (HFpEF) a Metabolic Disease?

  • Jyothis George Vice President - Clinical Development, Medical Affairs & Regulatory, , Novo Nordisk

Synopsis

  • Understand the metabolic syndrome and the major role obesity plays in this field
  • Highlight the correlation of obesity with HFpEF
  • Discuss effective methods to distinguish between obese patients with HFpEF from patients with other comorbidities

5:30 pm Moderated Discussion – Is HFpEF a Systemic or a Heart Disease?

6:00 pm Chair’s Closing Remarks

6:15 pm Close of Summit